[1] Tartaglia M, Niemeyer CM, Fragale A, et al.Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia[J]. Nature Genetics,2003, 34(2):148-150. [2] Bentires-Alj M, Paez JG, David FS, et al.Activating mutations of the noonan syndrome-associated SHP-2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia[J]. Cancer Res,2004, 64(24):8816-8820. [3] Loh ML, Reynolds MG, Vattikuti S, et al.PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the children's cancer group[J]. Leukemia, 2004,18(11):1831-1834. [4] Zheng H, Shawn Alter, Qu CK.SHP-2 tyrosine phosphatase in human diseases[J]. Int J Clin Exp Med, 2009, 2(1):17-25. [5] Marin TM, Keith K, Davies B, et al.Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of leopard syndrome-associated PTPN11 mutation[J]. J Clin Invest, 2011, 121(3):1026-1043. [6] Siying Wang, Wen-Mei Yu, Wanming Zhang, et al.Noonan syndrome/ leukemia- associated gain-of-function mutations in SHP-2 Phosphatase (PTPN11) enhance cell migration and angiogenesis[J]. J Biol Chem, 2009,284(2):913-920. [7] 张凤英, 余科科, 李菲菲, 等. SHP-2酪氨酸磷酸酶激活突变促进白细胞黏附和迁移的观察[J].安徽医科大学学报,2010, 45(4):487-490. [8] Yo K., Iwata S., HashizumeY., et al. SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration[J].Biochem Bioph Res Co, 2009, 382(1):210-214. [9] Zhu JX, Cao G, Williams JT, et al.SHP-2 phosphatase activity is required for PECAM-1-dependent cell motility[J]. Am J Physiol Cell Physiol, 2010, 299(4):854-865. [10] Qu CK.Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response[J]. Biochim Biophy Acta, 2002,1592(3):297-301. [11] Neel BG, Gu H, Pao L.The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling[J]. Trends Biochem Sci, 2003, 28(6):284-293. [12] ZQ Shi, DH Yu, Park M, et al.Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity[J]. Mol Cell Biol, 2000, 20(5):1526-1536. [13] Barford D, Neel BG.Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2[J]. Structure,1998, 6(1):249-254. [14] Wang SE, Y Yu, Criswell TL, et al. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators[J]. Oncogene, 2010, 29(23): 3335-3348. [15] Stefania Mitola, Barbara Brenchio, Marco Piccinini, et al.Type I collagen limits VEGFR-2 signaling by a SHP-2 Protein-Tyrosine phosphatase-dependent mechanism 1[J]. Circ Res, 2006, 98(1):45-54. [16] Bhattacharya R, Kwon J, Wang E, et al.Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration[J]. J Mol Signal, 2008, 3(8):315-324. [17] Liangping Yuan,Wen-Mei Yu, Min Xu, et al.SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2/M arrest in catalytically dependent and independent manners, respectively[J]. J Biol Chemistry, 2005, 280(52):42701-42706. [18] Ning Wang, Gerald D. Frank, Zhe Li, et al.Antagonism or synergism: role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling[J]. J Biol Chem, 2006, 281(31):21878-21883. [19] Tsui FW, Alberto Martin, John Wang, et al.Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase,SHP-1[J].Immunol Res, 2006, 35(1):127-136. [20] Kapoor GS, Zhan Y, Johnson GR, et al.Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-κB activation through Gab1 in glioblastoma cells[J]. Mol Cell Biol, 2004, 24(2):823-836. [21] Yao Lua, Yan Xionga,Yingqing Huoa, et al.Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway[J]. PNAS, 2011, 108(7):2957-2962. [22] Chang Hoon Ha, Anton M.Bennett, and Zheng-Gen Jin. A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor[D]. LMU München, 2007. [23] Nakashio A, Fujita N, Tsuruo T.Topotecan inhibits VEGF and bFGF-induced vascular endothelial cell migration via down regulation of the PI3K-Akt signaling pathway[J]. Int J Cancer, 2002, 98(1):36-41. [24] Hanna Karin Mannell, Vallentuna, Schweden,et al.The role of Src-homology 2 domain containin tyrosine phosphatase 2 in growth factor dependent endothelial signalling and angiogenesis[D]. LMU München, 2007. [25] Yu WM, Daino H, Chen J, et al.Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling[J]. Biol Chem, 2006, 281(9):5426-5434. [26] Liu X, Qu CK.Protein tyrosine phosphatase SHP-2 (PTPN11) in hematopoiesis and leukemogenesis[J]. Signal Transduct, 2011, 29(4):465-473. [27] Xu D, Wang S, Yu WM, et al.A germline gain-of-function mutation in ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells[J]. Blood, 2010, 116(18):3611-3621. [28] 张薇, 杨金莲, 胡中倩, 等. SHP-2酪氨酸磷酸酶激活突变导致小鼠髓系异常增殖[J].中国病理生理杂志, 2011, 27(4):682-687. [29] 张梅, 李菲菲, 郑红, 等. SHP-2酪氨酸磷酸酶在 DNA损伤性放化疗引发的小鼠骨髓毒中的作用[J]. 安徽医科大学学报, 2008, 43(5):480-484. [30] Allard WJ, Matera J, Miller MC, et al.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J].Clin Cancer Res, 2004, 10(20):6897-6904. |